Voyager Therapeutics (VYGR) Other Non Operating Income (2016 - 2026)
Voyager Therapeutics (VYGR) reported Other Non Operating Income of $435000.0 for Q1 2026, up 4.07% on a YoY basis from $418000.0 in Q1 2025, and up 412.95% sequentially from -$139000.0 in Q4 2025.
Voyager Therapeutics (VYGR) Other Non Operating Income (2016 - 2026) Analysis & Trends
Voyager Therapeutics (VYGR) has 11 years of Other Non Operating Income data on file, last reported at $435000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non Operating Income rose 4.07% year-over-year to $435000.0; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (up 7.98% YoY), and the FY2025 full-year result was $1.1 million, up 77.81% from the prior year.
- Other Non Operating Income advanced to $435000.0 in Q1 2026, from -$139000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $2.6 million in Q3 2022 to a low of -$139000.0 in Q4 2025.
- A 5-year average of $374769.2 and a median of $200000.0 in 2024 frame the typical range for Other Non Operating Income.
- Across the five-year window, Other Non Operating Income surged 2454.46% in 2022 and slumped 134.58% in 2025, its largest moves.
- Tracing VYGR's Other Non Operating Income over 5 years: stood at -$23000.0 in 2022, then jumped by 234.78% to $31000.0 in 2023, then jumped by 1196.77% to $402000.0 in 2024, then tumbled by 134.58% to -$139000.0 in 2025, then surged by 412.95% to $435000.0 in 2026.
- Business Quant data shows VYGR's Other Non Operating Income at $435000.0 in Q1 2026, -$139000.0 in Q4 2025, and $400000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Voyager Therapeutics | 184.74 Mn | 43.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 435,000.00 |
| Dec 31, 2025 | -139,000.00 |
| Sep 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 427,000.00 |
| Mar 31, 2025 | 418,000.00 |
| Dec 31, 2024 | 402,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Dec 31, 2023 | 31,000.00 |
| Jun 30, 2023 | 3,000.00 |
| Dec 31, 2022 | -23,000.00 |
| Sep 30, 2022 | 2.64 Mn |
| Jun 30, 2022 | 61,000.00 |
| Dec 31, 2021 | 650,000.00 |
| Sep 30, 2021 | -112,000.00 |
| Jun 30, 2021 | -1.58 Mn |
| Mar 31, 2021 | 3.92 Mn |
| Dec 31, 2020 | 7.72 Mn |
| Sep 30, 2020 | 830,000.00 |
| Jun 30, 2020 | -46,000.00 |